Hoofddorp, the Netherlands, 12 February 2020. IGEA Pharma N.V. (SIX: IGPH) today announced its intention to acquire a majority stake in Medical Jet Srl (“Medical Jet”), a privately held company operating in the pathogen’s decontamination of air and inanimate environmental surfaces and in air
sterilization and purification. A memorandum of understanding has been signed and subject to the satisfaction of certain customary conditions for a transaction of this type, IGEA expect to close the acquisition by June 2020. Further details of the transaction were not disclosed at this stage.
Medical Jet commercializes proprietary dry aerosol generators for a non-wet dispersion of pathogens decontaminants and proprietary air sterilization and purification devices using multiple filtering processes combined with germicidal UV-C ray technology. The combined action of aerosol dispersion and Rely+On Virkon® reduces a broad spectrum of viruses, bacteria and fungi. The acquisition strategy focuses on high cross-market synergies deriving from the previously announced understandings with Acalis and Meditalia respectively, emphasized by market penetration opportunities: the recent coronavirus outbreak highlights the relevance of pathogens sanitization in collective living environments. The need does not only rely on hospitals, clinics and medical or veterinarian surgeries, but touch also airports, other public transport environments, schools as well as many other environments with people concentration.
IGEA is a group focused on health-tech and med-tech products and devices. IGEA commercialize in the US Alz1 and Alz1 Tab, an at-home lab testing kit to measure non ceruloplasmin bound copper in the blood, and a natural dietary supplement designed to reduce blood heavy metals content respectively, and expects to start commercialization of Alz1 and Alz1 Tab in Middle East and some European and South American countries, including Belgium, Chile, Colombia, Uruguay and Peru in 2020. Non-bound (or “free”) copper is a risk factor associated with Alzheimer’s and diabetes type II. Monitoring and normalizing free copper can contribute to reduce the risk of Alzheimer’s and diabetes type II respectively. In 2020, IGEA expects to start commercialization in the EU and the US of polymeric based infusion and transfusion med-tech solutions.
IGEA is listed on the SIX Swiss Exchange under the ticker IGPH and is headquartered in Hoofddorp, the Netherlands.
Vincenzo Moccia, CEO
Tel +31 23 568 94 94/ +39 340 583 09 33
Patrick Pozzorini, CFO
Tel +31 23 568 94 94/ +41 79 314 41 43
IGEA Pharma N.V.
Siriusdreef 17, 2123 WT Hoofddorp, the Netherlands
This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in IGEA.
The information contained in this press release has been carefully prepared. However, IGEA bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. IGEA does not assume an obligation of whatever kind to update or correct
information contained in this press release whether as a result of new information, future events or for other reasons.
This publication may contain specific forward-looking statements and assessments or intentions concerning IGEA and its business. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between
the actual results, financial situation, development or performance of IGEA and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. IGEA assumes no responsibility to update forward-
looking statements or to adapt them to future events or developments, except as may be required by law.
Documents for download: